Galera presents supplemental analysis of phase III ROMAN trial at ECHNO

Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

If clinical research were anything like fly fishing, the scientific question that EA3163 trial attempted to answer might be considered “the one that got away”.

SU2C announces grants supporting research in six cancer types

Stand Up To Cancer announced grants to several teams of leading cancer investigators in support of cutting-edge research in a variety of cancers including head and neck, pediatric, pancreatic, breast, rectal, and gastro-esophageal cancers, as well as research focused on how the microbiome communicates with the immune system.

October 18, 2024

Vol.50 No.39

Clinical Roundup

Keytruda meets primary endpoint as perioperative treatment regimen in resected, locally advanced HNSCC

The phase III KEYNOTE-689 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, as a perioperative treatment for patients newly diagnosed with stage 3 or 4A, resected, locally advanced head and neck squamous cell carcinoma met its primary endpoint of event-free survival.

October 11, 2024

Vol.50 No.38

Clinical Roundup

Mayo Clinic performs world’s first known successful total larynx transplant in a patient with active cancer

A multidisciplinary team of doctors at Mayo Clinic in Arizona performed the third known total larynx transplant in the U.S.

July 12, 2024

Vol.50 No.28

Conversation with The Cancer Letter

Robert L. Ferris named executive director of UNC Lineberger—with an additional job as chief of oncology services

Robert L. Ferris, a head-and-neck surgeon and an expert in cancer immunotherapy was named the executive director of UNC Lineberger Comprehensive Cancer Center and the chief of oncology services at UNC Health.

Proton therapy demonstrates advantages for head and neck cancer in phase III trial preliminary data

According to preliminary data from a multi-institution phase III trial led by researchers at MD Anderson Cancer Center, intensity modulated proton therapy achieved similar clinical outcomes and offered significant patient benefits when compared to traditional intensity modulated radiation therapy as part of chemoradiation treatment for patients with oropharyngeal cancer.

June 07, 2024

Vol.50 No.23

Galera presents supplemental analysis of phase III ROMAN trial at ECHNO

YOU MAY BE INTERESTED IN

Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

SU2C announces grants supporting research in six cancer types

Keytruda meets primary endpoint as perioperative treatment regimen in resected, locally advanced HNSCC

Mayo Clinic performs world’s first known successful total larynx transplant in a patient with active cancer

Robert L. Ferris named executive director of UNC Lineberger—with an additional job as chief of oncology services

Proton therapy demonstrates advantages for head and neck cancer in phase III trial preliminary data

Renew today!

Subscriber content

Login